Drug intelligence / Profile preview

Lactobacillus plantarum SQ001

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum SQ001 is a specific strain of *Lactobacillus plantarum* isolated from the cecum of hyperuricemia (HUA) geese. It is being investigated as a probiotic therapy for hyperuricemia and gout. The strain works by improving the gut microbial community and facilitating hydrolase-mediated degradation of purine nucleosides. Mechanistically, it promotes nucleoside uptake and hydrolysis through its nucleoside hydrolase gene, downregulates hepatic xanthine oxidase (a key enzyme in uric acid synthesis), and modulates renal transporters by downregulating the reabsorption protein GLUT9 and enhancing the expression of the renal excretion protein ABCG2. These actions collectively contribute to reducing serum uric acid levels.

Targets

GLUT9 (Glucose transporter type 9)XO (Xanthine Oxidoreductase)NH4+ (Ammonium ion)ABCG2 (Breast cancer resistance protein)

Beyond the preview

Go deeper on Lactobacillus plantarum SQ001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus plantarum SQ001.

Explore the full profile